Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Gastrointestinal 3Endocrine 3Plasma cell 2Other 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1425Carcinoma, Renal Cell 586Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 123Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 77Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 50Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 43Neuroblastoma 39Uterine Cervical Neoplasms 38Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Head and Neck Neoplasms 26Clear-cell metastatic renal cell carcinoma 26

Interventions

cabazitaxel 1XRP6258 1Prednisone 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Diarrhea × Genitourinary × Clear all
NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡